JOYN Advisors’s Galectin Therapeutics GALT Stock Holding History

JOYN Advisors’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	$25K	Hold	12,796	–	–	0.01%	106
2019 Q4	$37K	Hold	12,796	–	–	0.01%	123
2019 Q3	$47K	Hold	12,796	–	–	0.01%	116
2019 Q2	$43K	Hold	12,796	–	–	0.01%	124
2019 Q1	$65K	Hold	12,796	–	–	0.02%	114
2018 Q4	$44K	Hold	12,796	–	–	0.01%	387
2018 Q3	$77K	Hold	12,796	–	–	0.01%	275
2018 Q2	$81K	Hold	12,796	–	–	0.02%	266
2018 Q1	$61K	Buy	+12,796	New	+$59.6K	0.01%	402

Other funds holding GALT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

JOYN Advisors's GALT Position: Q1 2020 in Review

JOYN Advisors held its Galectin Therapeutics (GALT) position steady in Q1 2020 at 12,796 shares worth $25K. The position accounts for 0.01% of the portfolio, ranked #106.

JOYN Advisors first reported a position in GALT in Q1 2018 and has held it in 9 quarters since. The position peaked at $81K in Q2 2018. 77 funds tracked by Wall St. Rank hold GALT as of Q1 2020.

JOYN Advisors held 12,796 shares of Galectin Therapeutics worth $25K as of Q1 2020.
JOYN Advisors left its Galectin Therapeutics share count unchanged in Q1 2020.
Galectin Therapeutics made up 0.01% of JOYN Advisors's portfolio in Q1 2020, its #106 holding.
JOYN Advisors first reported a position in Galectin Therapeutics in Q1 2018 and has held it in 9 quarters since.
JOYN Advisors's Galectin Therapeutics position peaked at $81K in Q2 2018.
77 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2020.

Based on JOYN Advisors's 13F filing for Q1 2020, filed 30 Apr 2020.